GlassScriptPhysician profile
Jennifer Bishop
NPI 1073777140
$3,045.24
in general payments reported to CMS, 2019-2025
34 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $84.72 · 2022: $43.84 · 2023: $1,159 · 2024: $1,006 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959 · Honoraria: $600 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.21 |
| Honoraria | $600.00 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $630.00 | 2023 | |
| Hologic Sales and Service, LLC | $540.60 | 2023-2024 | Localizer, Trunode, Mammosite |
| Novartis Pharmaceuticals Corporation | $385.17 | 2019-2024 | |
| Daiichi Sankyo INC. | $217.94 | 2022-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $183.94 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Axogen | $155.23 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Cap |
| Merck Sharp & Dohme LLC | $97.92 | 2023-2025 | Keytruda, Lenvima |
| Stryker Corporation | $95.97 | 2025 | Molli, Spy-Phi System |
| Biocomposites INC | $92.58 | 2024-2025 | Stimulan |
| Bayer Healthcare Pharmaceuticals INC. | $49.56 | 2023-2025 | |
| Kerecis Limited | $41.59 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Biotech, INC. | $37.66 | 2020 | |
| Beigene USA, INC. | $36.70 | 2024 | Brukinsa |
| Genmab U.S., INC. | $35.80 | 2024 | Epkinly |
| Exelixis INC. | $33.87 | 2019-2024 | Cabometyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $31.61 | 2024 | |
| Alexion Pharmaceuticals, INC. | $30.70 | 2024 | Ultomiris |
| Merit Medical Systems INC | $29.52 | 2022 | |
| Solventum Corporation | $28.81 | 2025 | Prevena Restor Bellaform, V.A.C. Veraflo, 3m Duraprep Surgical |
| Kyowa Kirin, INC. | $26.82 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.81 | 2023 | Libtayo |
| Beone Medicines USA, INC. | $24.41 | 2025 | Tevimbra |
| Eisai INC. | $22.88 | 2024 | |
| Glaxosmithkline, LLC. | $21.98 | 2025 | Ojjaara |
| Gilead Sciences, INC. | $21.10 | 2025 | Trodelvy |
| Acrotech Biopharma INC. | $20.78 | 2025 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $19.05 | 2020 | |
| Amgen INC. | $17.67 | 2019 | |
| Incyte Corporation | $17.64 | 2025 | Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.05 | 2024 | |
| Mindray Ds USA, INC. | $14.41 | 2024 | Te X, Te7 Max |
| Seagen INC. | $14.15 | 2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2023 | Augtyro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.